...
adpt-img

Adaptive Biotechnologies Corp, Common Stock

ADPT

NSQ

$5.97

-$0.55

(-8.44%)

1D
Industry: Life Sciences Tools & Services Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.00B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.72M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.45
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.28 L
$7.07 H
$5.97

About Adaptive Biotechnologies Corp, Common Stock

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. more

Industry: Life Sciences Tools & ServicesSector: Health Care

Returns

Time FrameADPTSectorS&P500
1-Week Return-6.43%-2.06%-0.55%
1-Month Return27.56%-1.92%2.72%
3-Month Return29.5%-10.4%7.66%
6-Month Return93.83%-4.6%10.15%
1-Year Return26.75%4.06%27.53%
3-Year Return-78.51%1.94%32.31%
5-Year Return-80.71%36.48%89.2%
10-Year Return-85.19%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue85.07M98.38M154.34M185.31M170.28M[{"date":"2019-12-31","value":45.91,"profit":true},{"date":"2020-12-31","value":53.09,"profit":true},{"date":"2021-12-31","value":83.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.89,"profit":true}]
Cost of Revenue22.27M22.53M49.30M57.91M75.55M[{"date":"2019-12-31","value":29.48,"profit":true},{"date":"2020-12-31","value":29.82,"profit":true},{"date":"2021-12-31","value":65.25,"profit":true},{"date":"2022-12-31","value":76.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit62.80M75.85M105.04M127.40M94.72M[{"date":"2019-12-31","value":49.29,"profit":true},{"date":"2020-12-31","value":59.54,"profit":true},{"date":"2021-12-31","value":82.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.35,"profit":true}]
Gross Margin73.82%77.10%68.06%68.75%55.63%[{"date":"2019-12-31","value":95.74,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":88.27,"profit":true},{"date":"2022-12-31","value":89.17,"profit":true},{"date":"2023-12-31","value":72.15,"profit":true}]
Operating Expenses141.19M228.67M314.01M327.58M321.76M[{"date":"2019-12-31","value":43.1,"profit":true},{"date":"2020-12-31","value":69.8,"profit":true},{"date":"2021-12-31","value":95.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.22,"profit":true}]
Operating Income(78.39M)(152.82M)(208.97M)(200.19M)(227.03M)[{"date":"2019-12-31","value":-7839100000,"profit":false},{"date":"2020-12-31","value":-15281700000,"profit":false},{"date":"2021-12-31","value":-20896600000,"profit":false},{"date":"2022-12-31","value":-20018600000,"profit":false},{"date":"2023-12-31","value":-22703500000,"profit":false}]
Total Non-Operating Income/Expense19.57M13.18M3.34M(364.00K)878.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.35,"profit":true},{"date":"2021-12-31","value":17.05,"profit":true},{"date":"2022-12-31","value":-1.86,"profit":false},{"date":"2023-12-31","value":4.49,"profit":true}]
Pre-Tax Income(68.61M)(146.23M)(207.30M)(200.37M)(225.30M)[{"date":"2019-12-31","value":-6860600000,"profit":false},{"date":"2020-12-31","value":-14622700000,"profit":false},{"date":"2021-12-31","value":-20729800000,"profit":false},{"date":"2022-12-31","value":-20036800000,"profit":false},{"date":"2023-12-31","value":-22530400000,"profit":false}]
Income Taxes(9.79M)(6.59M)(1.69M)(57.90M)(54.00K)[{"date":"2019-12-31","value":-978500000,"profit":false},{"date":"2020-12-31","value":-659000000,"profit":false},{"date":"2021-12-31","value":-168700000,"profit":false},{"date":"2022-12-31","value":-5790400000,"profit":false},{"date":"2023-12-31","value":-5400000,"profit":false}]
Income After Taxes(58.82M)(139.64M)(205.61M)(142.46M)(225.25M)[{"date":"2019-12-31","value":-5882100000,"profit":false},{"date":"2020-12-31","value":-13963700000,"profit":false},{"date":"2021-12-31","value":-20561100000,"profit":false},{"date":"2022-12-31","value":-14246400000,"profit":false},{"date":"2023-12-31","value":-22525000000,"profit":false}]
Income From Continuous Operations(68.61M)(146.23M)(207.30M)(200.37M)(196.01M)[{"date":"2019-12-31","value":-6860600000,"profit":false},{"date":"2020-12-31","value":-14622700000,"profit":false},{"date":"2021-12-31","value":-20729800000,"profit":false},{"date":"2022-12-31","value":-20036800000,"profit":false},{"date":"2023-12-31","value":-19600600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(58.82M)(139.64M)(205.61M)(142.46M)(225.25M)[{"date":"2019-12-31","value":-5882100000,"profit":false},{"date":"2020-12-31","value":-13963700000,"profit":false},{"date":"2021-12-31","value":-20561100000,"profit":false},{"date":"2022-12-31","value":-14246400000,"profit":false},{"date":"2023-12-31","value":-22525000000,"profit":false}]
EPS (Diluted)(1.69)(1.11)(1.47)(1.41)(1.38)[{"date":"2019-12-31","value":-169,"profit":false},{"date":"2020-12-31","value":-111,"profit":false},{"date":"2021-12-31","value":-147,"profit":false},{"date":"2022-12-31","value":-141,"profit":false},{"date":"2023-12-31","value":-138,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ADPT
Cash Ratio 2.78
Current Ratio 3.52
Quick Ratio 3.38

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ADPT
ROA (LTM) -16.37%
ROE (LTM) -66.76%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ADPT
Debt Ratio Lower is generally better. Negative is bad. 0.60
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.40

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ADPT
Trailing PE NM
Forward PE NM
P/S (TTM) 5.43
P/B 4.30
Price/FCF NM
EV/R 4.57
EV/Ebitda NM
PEG NM

FAQs

What is Adaptive Biotechnologies Corp share price today?

Adaptive Biotechnologies Corp (ADPT) share price today is $5.97

Can Indians buy Adaptive Biotechnologies Corp shares?

Yes, Indians can buy shares of Adaptive Biotechnologies Corp (ADPT) on Vested. To buy Adaptive Biotechnologies Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Adaptive Biotechnologies Corp be purchased?

Yes, you can purchase fractional shares of Adaptive Biotechnologies Corp (ADPT) via the Vested app. You can start investing in Adaptive Biotechnologies Corp (ADPT) with a minimum investment of $1.

How to invest in Adaptive Biotechnologies Corp shares from India?

You can invest in shares of Adaptive Biotechnologies Corp (ADPT) via Vested in three simple steps:

  • Click on Sign Up or Invest in ADPT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Adaptive Biotechnologies Corp shares
What is Adaptive Biotechnologies Corp 52-week high and low stock price?

The 52-week high price of Adaptive Biotechnologies Corp (ADPT) is $7.07. The 52-week low price of Adaptive Biotechnologies Corp (ADPT) is $2.28.

What is Adaptive Biotechnologies Corp price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Adaptive Biotechnologies Corp (ADPT) is

What is Adaptive Biotechnologies Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Adaptive Biotechnologies Corp (ADPT) is 4.30

What is Adaptive Biotechnologies Corp dividend yield?

The dividend yield of Adaptive Biotechnologies Corp (ADPT) is 0.00%

What is the Market Cap of Adaptive Biotechnologies Corp?

The market capitalization of Adaptive Biotechnologies Corp (ADPT) is $1.00B

What is Adaptive Biotechnologies Corp’s stock symbol?

The stock symbol (or ticker) of Adaptive Biotechnologies Corp is ADPT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top